Richard J. Massey, PhD

Dr. Richard J. Massey was President and Chief Operating Officer of BioVeris Corporation and prior to that IGEN International, Inc. BioVeris was an integrated healthcare company, based in Gaithersburg, Maryland, that developed proprietary diagnostics and vaccines. BioVeris was publicly traded and resulted from the merger between IGEN International, Inc. and F. Hoffmann-La Roche Ltd. Dr. Massey was a co-founder of IGEN International, Inc.

Dr. Massey managed the research and development programs, intellectual property portfolio and operations at IGEN International, Inc. and BioVeris from 1982 to 2004. Prior to IGEN International, Inc., he was on the faculty of Rush Medical College, Chicago and a Senior Scientist at the National Cancer Institute, Frederick Cancer Research Center.

He has recently established a foundation to support fellowships in the arts and sciences. Dr. Massey is a visiting Professor at Lund University, Sweden, a member of the board of directors for Exit Art, the Armitage Foundation and the Metropolitan Opera in New York and a member of the committee for media and performance at the Museum of Modern Art, New York. He also serves on an advisory board for the University of Illinois in Chicago. Dr. Massey has published numerous scientific articles related to the study of viruses that cause cancer, host immune responses to tumors and electrochemiluminescence methods for analytical measurements. Dr. Massey has been awarded over 200 patents.

Dr. Massey received his BS, MS, and PhD degrees from the University of Illinois.